In preclinical studies, the inhibition of FAK decreases the recruitment and migration of CAFs, MDSCs, TAMs, and Treg cells, ultimately leading to increased CD8+ T cell infiltration and cancer cell suppression [102,103]. The gene discussed is CD8A; the disease is cancer.